^
Association details:
| Biomarker: | ATRX deletion |
|---|---|
| Cancer: | Glioma |
| Drug: | Sutent (sunitinib) (c-KIT inhibitor, VEGFR inhibitor, PDGFR inhibitor) + temozolomide (DNA synthesis inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
ATRX-deficient glioma cells exhibit increased sensitivity to multi-targeted receptor tyrosine kinase inhibitors
Published date:
05/28/2021
Excerpt:
We treated three different cell lines (one astrocytoma and two glioblastoma) with four different RTK inhibitors, confirming the higher sensitivity of ATRX-deficient cells….temozolomide and RTK inhibitors may increase the therapeutic window of opportunity in glioma patients with ATRX mutations.
